Crossmark

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib

Crossref DOI link: https://doi.org/10.1038/s41375-024-02353-0

Published Online: 2024-07-31

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Leyte-Vidal, Ariel

DeFilippis, RosaAnna http://orcid.org/0009-0006-1365-235X
Outhwaite, Ian R. http://orcid.org/0000-0003-2037-3261
Kwan, Isabelle

Lee, Ji Young http://orcid.org/0000-0002-1491-6963
Leavitt, Carlyn

Miller, Kaeli B.

Rea, Delphine http://orcid.org/0000-0001-5379-7461
Rangwala, Aziz M. http://orcid.org/0000-0003-3556-7931
Lou, Kevin

Patel, Suhana

Alvarez, Ailin

Shokat, Kevan M.

Bahar, Ivet

Seeliger, Markus A. http://orcid.org/0000-0003-0990-1756
Shah, Neil P. http://orcid.org/0000-0003-4398-3388
Funding

Funding for this research was provided by:

American Society of Hematology (A141755)

U.S. Department of Health & Human Services | National Institutes of Health (NIH T32GM136572, T32GM008444, 1R01CA281984, R01GM139297, R35GM119437)

U.S. Department of Health & Human Services | National Institutes of Health

U.S. Department of Health & Human Services | National Institutes of Health

Samuel Waxman Cancer Research Foundation

U.S. Department of Health & Human Services | National Institutes of Health

U.S. Department of Health & Human Services | National Institutes of Health
License Information

Text and Data Mining valid from 2024-07-31

Version of Record valid from 2024-07-31
More Information

Article History

Received: 23 June 2024

Revised: 4 July 2024

Accepted: 10 July 2024

First Online: 31 July 2024

Competing interests

: NPS has received funding from Bristol-Myers Squibb Oncology for the conduct of clinical research. DR has served on an Advisory Board, Steering Committee and as a Consultant for Novartis Pharmaceuticals. KMS has consulting agreements with the following companies, which involve monetary and/or stock compensation: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Kumquat Biosciences, Kura Oncology, Mitokinin, Nested, Novartis, Type6 Therapeutics, Wellspring Biosciences (Araxes Pharma), Initial Therapeutics, Vevo and BioTheryX. Kin of K.L. hold stock in and are employed by Pharmaron. The remaining authors have no conflicts of interest to disclose.

Document is current

Any future updates will be listed below